Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARDs (bDMARDs) and other novel DMARDs for second-line...

Full description

Bibliographic Details
Main Authors: Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:International Journal of Rheumatology
Online Access:http://dx.doi.org/10.1155/2017/8417249

Internet

http://dx.doi.org/10.1155/2017/8417249

Similar Items